Ahmedabad: Homegrown Pharmaceutical SpecialistTorrent Pharmaceuticals Limited, recorded a 52% growth in its profit after tax (PAT) to Rs 443 crore in the third quarter of FY2024, from Rs 292 crore for the corresponding quarter last year.
The growth was driven by four launches in 2022 and three launches in 2023, as well as the performance of leading brands and growth in the generics business, the company said in its stock exchange filing.
The company's board of directors approved an interim dividend of Rs 22 per share. TN
We also published the following articles recently.
The growth was driven by four launches in 2022 and three launches in 2023, as well as the performance of leading brands and growth in the generics business, the company said in its stock exchange filing.
The company's board of directors approved an interim dividend of Rs 22 per share. TN
We also published the following articles recently.
Torrent Pharma's after-tax profit increases 52% in the third quarter
Torrent Pharmaceuticals Limited reported a 52% growth in consolidated net profit for Q3 FY2024, reaching Rs 443 crore. The company attributed the growth to launches in 2022 and 2023, the performance of major brands and growth in the generic business. The board also approved an interim dividend of Rs 22 per share.
Torrent Pharmaceuticals Limited reported a 52% growth in consolidated net profit for Q3 FY2024, reaching Rs 443 crore. The company attributed the growth to launches in 2022 and 2023, the performance of major brands and growth in the generic business. The board also approved an interim dividend of Rs 22 per share.
